Share on WeChat
Open WeChat, click “Discovery” below, |
The negotiation work of the 2022 National Medical Insurance Drug List officially concluded on January 8. Compared to the previous two years, the number of drugs participating in this medical insurance negotiation has increased significantly. This year, a total of three drugs for the treatment of COVID-19, Azivudine Tablets, Naimatevir Tablets/Ritonavir Tablets Combination Packaging and Qingfei Paidu Granules, participated in the negotiation through the self-registration, form review and expert review procedures. Among them, Azivudine Tablets and Qingfei Paidu Granules were successfully negotiated, but Paxlovid failed due to the high listing of the manufacturer Pfizer Investment Co., Ltd.
The new crown drug medical insurance catalog announced that Azvudine Tablets and Qingfei Paidu Granules were on the list
The negotiation work of the 2022 National Medical Insurance Drug List officially concluded on January 8. Compared to the previous two years, the number of drugs participating in this medical insurance negotiation has increased significantly. This year, a total of three drugs for the treatment of COVID-19, Azivudine Tablets, Naimatevir Tablets/Ritonavir Tablets Combination Packaging and Qingfei Paidu Granules, participated in the negotiation through the self-registration, form review and expert review procedures. Among them, Azivudine Tablets and Qingfei Paidu Granules were successfully negotiated, but Paxlovid failed due to the high listing of the manufacturer Pfizer Investment Co., Ltd.
